About Affimed N.V
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Corporation; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. and Roche. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson’s NK-cell product; Genentech; and Roivant Sciences. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany. Address: Technologiepark, Heidelberg, Germany, 69120
Affimed N.V News and around…
Latest news about Affimed N.V (AFMD) common stock and company :
Is Affimed NV (NASDAQ:AFMD) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]
Upgrades For Coterra Energy Inc (NYSE:CTRA), Piper Sandler upgraded the previous rating of Neutral to Overweight. The current stock ...
Anavex Life Sciences and Affimed both sport unique drug development platforms that could be worth billions.
In this article, we take a look at the 10 pharmaceutical stocks to buy according to Timothy Lynch’s Stonepine Capital. If you want to skip our detailed analysis of Stonepine Capital’s history, investment philosophy, and hedge fund preference, go directly to 5 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital. Timothy Lynch is […]
HEIDELBERG, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three abstracts with preclinical data of its innate cell engagers have been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held on November 10-14, 2021. Abstract details: Title: Tetravalent, bispecific in
Upgrades For Cabot Oil & Gas Corp (NYSE:COG), Wolfe Research upgraded the previous rating of Peer Perform to Outperform. For the ...
AFMD, FSLR, MU, BCE, and USNA have been added to the Zacks Rank #5 (Strong Sell) List on September 29, 2021.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Russell 2000—Dynamic Multifactor ETF (OMFS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $48.67 per unit.
AFMD, DZSI, GMBL, NTRB, and SURF have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2021.
AFMD earnings call for the period ending June 30, 2021.
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -171.43% and -13.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
Companies Reporting Before The Bell • Nanobiotix (NASDAQ:NBTX) is likely to report earnings for its first ...
Biotech stocks extended their gains in the week endingSept. 3, partly aided by the broader market strength. The news flow was ...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Russell 2000—Dynamic Multifactor ETF (OMFS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $47.39 per unit.
The last three months have been tough on Affimed N.V. ( NASDAQ:AFMD ) shareholders, who have seen the share price...
Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In this article, we discuss the 15 stocks that will double in 2021. If you want to skip our detailed analysis of these stocks, go directly to the 5 Stocks that Will Double In 2021. The economy of 2020 was closely linked to the COVID-19 pandemic. However, the vaccine rollout at the turn of the […]
Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.
Wall Street analysts following these drugmakers think they can produce big gains in a short time frame.
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
In trading on Wednesday, shares of Affimed N. .
Shares of Affimed (NASDAQ:AFMD) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved ...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..